Clinical trials: Aggressive Behaviour
Lymphoma, Large-Cell, Diffuse
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the safety and efficacy of ofatumumab used in combination with ifosfamide, carboplatin, etoposide (ICE) or dexamethasone, cytarabine, cisplatin (DHAP) salvage chemotherapy regimens in…
- Trial name
- NCT00823719
- Testing
- ofatumumab + ICE, ofatumumab + DHAP
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Intermittent Explosive Disorder
A Cognitive Bias Modification RCT for Aggression
This randomized controlled trial will test a computerized cognitive bias modification program (CBM) to treat attention and interpretive biases in patients with primary aggression.
- Trial name
- NCT04819230
- Testing
- Cognitive Bias Modification, Cognitive Bias Control
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Temple University
Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Trial name
- NCT07179783
- Testing
- Sacituzumab Tirumotecan, Tagitanlimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Second Hospital
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- uPAR-PET (NCT02437539)
- Testing
- Injection of 68Ga-NOTA-AE105, Positron Emission Tomography scans
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Squamous Cell Carcinoma
Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients
To identify risk factors for aggressiveness in Squamous Cell Carcinoma of the skin in organ transplant recipients.
- Trial name
- NCT02095912
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma.
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma
- Trial name
- NCT05025800
- Testing
- CD47 Antagonist ALX148, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Periodontal Disease
Polymorphonuclear Cells' Sensitivity to Aggregatibacter Actinomycetemcomitans Bacteria in Patients With Aggressive Periodontitis
aggressive periodontitis is an inflammatory disease which damage the teeth supporting structures mostly in young patients. and has genetic basis.
- Trial name
- NCT02010307
- Testing
- blood extraction
- Where
- Israel
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Polak David
Conduct Disorder, ADHD
Investigation of Psychophysiological Correlation of Aggression and Response to Aversive Stimuli
This study investigates the psychophysiological correlations of aggression and response to aversive stimuli in a population of 133 children clinically diagnosed with conduct disorder (CD) and/or attention-deficit/hyperactivity…
- Conditions
- Conduct Disorder, ADHD, Oppositional Defiant Disorder
- Trial name
- NCT03725371
- Testing
- No intervention was administered for the purpose of this study.
- Volunteers
- 133 people
- Sponsor
- Yale-NUS College
Thyroid Cancer
This Study is Mainly About Finding Incidence Among Other Factors of Thyroid Cancer in Patient with Benign Disease As MNG to Early Discover of the Malignancy to Save the Patient from Aggressive Procedure
The purpose of the present study was to evaluate the prevalence of thyroid cancer in patients who had thyroidectomy for MNG, and analyze patient-related parameters to identify type and risk factors associated with incidental…
- Trial name
- NCT06730971
- Testing
- Total thyroidectomy
- Volunteers
- 300 people
- Sponsor
- Asmaa Mohamed Emam
L-PRF, Photodynamic Therapy
The Effect of Leukocyte and Platelet-rich Fibrin With Antimicrobial Photodynamic Therapy in Aggressive Periodontitis
Antimicrobial photodynamic therapy (aPDT) is associated with photosensitizing agents which promote the generation of free radicals and singlet oxygen, which are cytotoxic to certain bacteria.
- Conditions
- L-PRF, Photodynamic Therapy, Aggressive Periodontitis
- Trial name
- NCT05043935
- Testing
- L-PRF with antimicrobial photodynamic therapy, antimicrobial photodynamic therapy without L-PRF
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Acute Myelogenous Leukemia
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
This was initially a phase I/II, open-label non-randomized study using an investigational new drug, TL32711, in patients with AML, MDS and ALL, however, the phase II portion was never initiated.
- Trial name
- NCT01486784
- Testing
- Birinapant
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Anemia, Neoplasms
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa in the treatment of persistent anemia caused by advanced cancer and aggressive adriamycin-chemotherapy.
- Trial name
- NCT00266617
- Testing
- epoetin alfa
- Volunteers
- 86 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Non-Hodgkins Lymphoma
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.
- Trial name
- NCT00179660
- Testing
- Lenalidomide
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celgene Corporation
Spinal Metastases
Evaluation of Spinal Metastatic Tumour for Aggressive Spinal Sugery by Dual Energy CT
Metastatic vertebral disease is a major hazard for oncological patients because the performance and life quality will substantially deteriorate if presence of neoplastic compression.
- Trial name
- NCT03631095
- Where
- Taiwan
- Volunteers
- 61 people
- Sponsor
- National Taiwan University Hospital
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
The purpose of this study is to evaluate the safety and efficacy of Zevalin® in a Reduced Intensity Conditioning regimen followed by allogenic stem cell support in patients with aggressive lymphomas who are responsive to a…
- Trial name
- ZEVALLO (NCT00607854)
- Testing
- Ibritumomab Tiuxetan (Zevalin)
- Where
- 12 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Bordeaux
Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases.
- Conditions
- Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia, Systemic Chronic Active Epstein-Barr Virus Disease, Epstein-Barr Virus-Positive Nodal T/NK-Cell Lymphoma
- Trial name
- EBV-T/NK Cohor (NCT07727083)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Rong Tao
Autism
Oxcarbazepine Versus Placebo in Childhood Autism
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism.
- Trial name
- NCT00467753
- Testing
- Oxcarbazepine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Schizophrenia
Clozapine IM and Aggression in Schizophrenic Patients
Aggressive, persistent aggression and impulsive behavior are frequently observed in schizophrenic patients. According to some researchers "more than 50% of all psychiatric patients and 10% of schizophrenic patients show…
- Trial name
- NCT00189995
- Testing
- clozapine, haloperidol
- Where
- 2 sites in Israel
- Sponsor
- Beersheva Mental Health Center
Aggression
Aggressive Incidents in Medical Settings Study
The purpose of this study is to identify the incidence rate and characteristics of aggressive behavior perpetrated by patients and visitors in inpatient medical units and to understand the role of missed care events, professional…
- Trial name
- AIMS (NCT03041272)
- Where
- 3 sites in United States
- Volunteers
- 137 people
- Sponsor
- Yale University
Myocardial Ischemia
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or nonfatal MI.
- Trial name
- NCT00007657
- Testing
- Intensive medical therapy, Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
- Where
- 48 sites in United States, Canada
- Volunteers
- 3,260 people
- Sponsor
- US Department of Veterans Affairs